Vaccines and diagnostics today only reach places with functioning cold chains. This logistical bottleneck has limited healthcare in much of Africa, Southeast Asia, and Latin America for decades. A team led by Keith Pardee at the University of Toronto has developed a technology that could change this: freeze-dried, cell-free bioproduction, deployable without power, refrigeration, or specialized equipment. The study appeared May 29, 2026 in Science Advances.
The problem: the cold chain as an invisible barrier
Vaccines only work if the active ingredient hasn't degraded. Most must be stored and transported at two to eight degrees Celsius; some require minus seventy degrees. In Western Europe and North America, that's hardly a problem. In remote regions without stable electricity, refrigerated vehicles, or storage capacity, the chain breaks regularly. The World Health Organization counts cold-chain failures as a leading cause of vaccine waste in resource-poor countries.
Then there's the production side. Nearly all biological agents—vaccines, diagnostic proteins, antibodies, and therapeutic enzymes—are manufactured in specialized facilities in North America, Europe, and parts of Asia. Outbreaks and pandemics repeatedly show what this means: local demand cannot be met quickly enough from central stockpiles.
What the Toronto team developed
Pardee and his team use cell-free protein synthesis. They extract and purify the molecular production machinery of life from bacteria: ribosomes, polymerases, energy carriers, and every other component a cell needs to manufacture proteins—without living cells involved. These reagents are then freeze-dried, similar to instant coffee. The result is stable powders that can be stored and shipped without refrigeration. To produce biological agents, you simply add water to the powder.
For centrifugation steps needed in many production processes, researchers developed a 3D-printed hand-crank centrifuge. It costs just a few dollars, requires no electricity, and works in any environment. According to the Science Advances paper, the systems were deployed at ten sites worldwide, including teams in Bogotá, Colombia; Santiago, Chile; and Recife, Brazil. Local teams without specialized molecular biology training could manufacture vaccine candidates, diagnostic enzymes, and research proteins.
A comparison: MenAfriVac and the cold-chain revolution
A similar turning point came for meningitis vaccination in Africa in the early 2010s. MenAfriVac, the first meningitis-A vaccine developed for the African market, became in 2012 the first vaccine globally approved for use outside strict cold-chain requirements. It can be stored for up to four days at 104 degrees Fahrenheit. Technically it sounds minor. Practically, it was a watershed for distribution in remote regions without continuous refrigeration. Over 300 million people in Africa's so-called meningitis belt have since been vaccinated. Epidemic meningitis A has nearly disappeared in those regions.
The crucial difference from Pardee's approach: MenAfriVac was a centrally produced vaccine with an extended cold chain. The Toronto technology targets decentralized, local manufacturing. Not only storage but production itself should happen on site.
A second comparison: during the COVID-19 pandemic, the Pfizer-BioNTech vaccine required minus 112 degrees Fahrenheit storage. In many African countries, distribution failed because of this. Health posts that couldn't accommodate the vaccine sent deliveries back. Millions of doses were destroyed. A cold-chain-independent, locally producible alternative would have solved this problem structurally, not through logistics, but through technology.
Three steps to broad deployment
The technology is proven but not yet approved for medical use. Three steps are missing. First, regulatory approval: decentrally produced vaccines must be reviewed by national and international agencies. For standardized procedures with consistent results, this is feasible but requires extensive quality documentation.
Second, training and knowledge transfer. The ten pilot sites in the study are research institutions. Health posts in rural regions have less trained staff. The team has developed open software tools and simplified protocols intended to work even without molecular biology expertise.
Third, funding for scaling. The U.S. National Science Foundation provided over forty million dollars in 2024 through the CFIRE program for cell-free system development. Similar programs through GAVI or the Coalition for Epidemic Preparedness Innovations (CEPI) could accelerate the transition from lab to practice. The ten pilot sites are the first step. Whether health posts in sub-Saharan Africa and South Asia follow depends on how quickly regulation, training, and funding align.